View ValuationBiofrontera 将来の成長Future 基準チェック /06現在、 Biofronteraの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長10.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 02Biofrontera AG, Annual General Meeting, Jun 10, 2026Biofrontera AG, Annual General Meeting, Jun 10, 2026, at 10:00 W. Europe Standard Time.Reported Earnings • Apr 24Full year 2025 earnings released: €1.12 loss per share (vs €0.70 loss in FY 2024)Full year 2025 results: €1.12 loss per share (further deteriorated from €0.70 loss in FY 2024). Revenue: €13.2m (up 8.3% from FY 2024). Net loss: €6.81m (loss widened 61% from FY 2024). Over the last 3 years on average, earnings per share has increased by 117% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.お知らせ • Oct 24Biofrontera Inc. (NasdaqCM:BFRI) completed the acquisition of US Assets related to Ameluz and RhodoLED of Biofrontera AG.Biofrontera Inc. (NasdaqCM:BFRI) signed an agreement to acquire US Assets related to Ameluz and RhodoLED of Biofrontera AG on June 30, 2025. The transaction coupled with an $11 million financing led by existing investors, Rosalind Advisors and AIGH Capital Management LLC, funded the acquisition and transfer costs. Upon completion, Biofrontera Inc. will pay a monthly Ameluz® royalty of 12% in years where Ameluz® revenue in the US is less than $65 million, and 15% in years when revenue exceeds that threshold. The new royalty replaces the former transfer pricing model which required payment of 25% to 35% of the net sales price per tube depending on timing and indication. As part of the agreement, Biofrontera AG will receive a 10% post-money equity stake in Biofrontera Inc., aligning long-term interests between the entities. Biofrontera Inc. (NasdaqCM:BFRI) completed the acquisition of US Assets related to Ameluz and RhodoLED of Biofrontera AG on October 23, 2025. On completion, Biofrontera Inc. now assumes full responsibility for manufacturing, regulatory, quality management, pharmacovigilance, and commercialization of Ameluz ® and the RhodoLED ® portfolio in the U.S. The Company expects the full transfer of assets and personnel to be completed by late Q4 2025 or early Q1 2026.お知らせ • Apr 18Biofrontera AG, Annual General Meeting, May 28, 2025Biofrontera AG, Annual General Meeting, May 28, 2025, at 10:00 W. Europe Standard Time.お知らせ • Dec 16+ 3 more updatesBiofrontera AG to Report Fiscal Year 2024 Results on Apr 30, 2025Biofrontera AG announced that they will report fiscal year 2024 results at 12:00 PM, Central European Standard Time on Apr 30, 2025お知らせ • Nov 24Biofrontera AG announced that it has received $4.2 million in fundingBiofrontera Inc. announced a private placement to issue senior secured convertible note for the gross proceeds of $4,200,000 on November 22, 2024. The transaction included participation from two majority shareholders. The Note matures on November 22, 2027, bears a paid in kind interest of 10% per annum and is secured by the Company’s assets. The principal amount of the Note in whole or in part is convertible into common shares at the holder’s discretion at a fixed conversion price of $0.78. Alternatively, the entire amount of the note will be automatically converted to common shares if the 10-day volume weighted average price (VWAP) of Company shares on Nasdaq is greater than $2.50, and certain other conditions are met. The Notes contain customary restrictive covenants that, among other things, generally limit the ability of the Company to (i) create liens, (ii) pay dividends or acquire shares of capital stock, (iii) incur indebtedness, or (iv) enter into transactions with affiliates. The foregoing restrictive covenants are subject to a number of important exceptions and qualifications, as set forth in the Notes.お知らせ • Sep 26Biofrontera AG to Report First Half, 2024 Results on Sep 30, 2024Biofrontera AG announced that they will report first half, 2024 results on Sep 30, 2024お知らせ • Jul 23Biofrontera AG, Annual General Meeting, Aug 28, 2024Biofrontera AG, Annual General Meeting, Aug 28, 2024, at 10:00 W. Europe Standard Time.お知らせ • May 16Biofrontera AG to Report Q1, 2024 Results on May 31, 2024Biofrontera AG announced that they will report Q1, 2024 results on May 31, 2024お知らせ • Apr 24Biofrontera AG to Report Fiscal Year 2023 Results on Apr 30, 2024Biofrontera AG announced that they will report fiscal year 2023 results at 12:00 PM, Central European Standard Time on Apr 30, 2024お知らせ • Nov 07Biofrontera AG to Report Q3, 2023 Results on Nov 28, 2023Biofrontera AG announced that they will report Q3, 2023 results on Nov 28, 2023お知らせ • Jul 14Biofrontera AG to Report First Half, 2023 Results on Aug 31, 2023Biofrontera AG announced that they will report first half, 2023 results on Aug 31, 2023お知らせ • Jul 06Biofrontera Launches Novel Belixos Active CareBiofrontera announced that the active cosmetic series belixos has been extended by the care foam belixos ACTIVE CARE. belixos ACTIVE CARE is a skin-so clothing care foam for irritated and itchy skin that can be used as basic care for atopic dermatitis and psoriasis, as well as for soothing intensive care for everyday skin problems. With its innovative formulation as a foam, it provides a pleasant feeling on the skin without a greasy film and enables particularly gentle application of the high-quality ingredients as a result of the reduced foam formulation. Due to it's innovative nature, Biofrontera was able to register the underlying innovative foam formulation as a patent. As previously in the belixos cosmetics series, the focus is on the traditional medicinal plant Mahonia as an active component. The medicinal plant, which is still quite unknown in European country but has been used for centuries in the medicine of the indigenous people of North America, is known to have anti-inflammatory, antipruritic and antiseptic properties. With the help of Biofrontera's proprietary biocolloid technology, the plant-based active ingredients penetrate very quickly into the epidermis and distribute there in order to unfold their soothing and regenerating effect in this very sensitive layer of skin that is particularly accessible to external influences.お知らせ • May 30Biofrontera AG to Report Q1, 2023 Results on May 31, 2023Biofrontera AG announced that they will report Q1, 2023 results on May 31, 2023お知らせ • May 18Biofrontera AG Completes Patient Recruitment of Ameluz Phase I TrialBiofrontera AG announced the successful completion of the Phase I study evaluating the safety and tolerability of Ameluz-PDT for the treatment of actinic keratosis (AK) with 3 tubes of Ameluz. This trial was conducted to expand the approval of Ameluz in the United States so that larger areas of AK-affected skin can be treated in one therapy session. The study involved 100 patients with mild to severe actinic keratosis, each of them receiving the contents of 3 tubes of Ameluz for a field-directed treatment of AK. Illumination was provided by Biofrontera's novel, larger RhodoLED XL lamp. The first results of the study are expected in the fourth quarter of 2023.お知らせ • May 13Biofrontera AG, Annual General Meeting, Jun 20, 2023Biofrontera AG, Annual General Meeting, Jun 20, 2023, at 11:30 Central European Standard Time. Location: Forum Leverkusen, Agam-Saal, Am Büchelter Hof 9, Leverkusen GermanyReported Earnings • Apr 30Full year 2022 earnings released: €0.77 loss per share (vs €0.69 profit in FY 2021)Full year 2022 results: €0.77 loss per share (down from €0.69 profit in FY 2021). Revenue: €25.7m (down 11% from FY 2021). Net loss: €44.2m (down 215% from profit in FY 2021). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Biofrontera は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測LSE:0DOL - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202513-7-4-4N/A9/30/202523-2N/AN/AN/A3/31/202524-1N/AN/AN/A12/31/2024121-3-3N/A9/30/2024180N/AN/AN/A6/30/202422-3-5-4N/A3/31/2024300N/AN/AN/A12/31/2023320-3-2N/A9/30/202329-9N/AN/AN/A6/30/202328-11-4-3N/A3/31/202325-20N/AN/AN/A12/31/202226-44-5-4N/A9/30/20223211N/AN/AN/A6/30/202231103333N/A3/31/20223015N/AN/AN/A12/31/202129383030N/A9/30/202128-16N/AN/AN/A6/30/202127-16-8-7N/A3/31/202129-12N/AN/AN/A12/31/202030-13-4-3N/A9/30/202033-17N/AN/AN/A6/30/202033-22-14-12N/A3/31/202031-10N/AN/AN/A12/31/201931-7-35-33N/A9/30/2019261N/AN/AN/A6/30/2019268N/A-28N/A3/31/201923-8N/AN/AN/A12/31/201821-9N/A-13N/A9/30/201819-14N/A-13N/A6/30/201816-15N/A-12N/A3/31/201814-16N/AN/AN/A12/31/201712-16N/A-13N/A9/30/201711-18N/A-16N/A6/30/20179-16N/A-16N/A3/31/20178-14N/A-15N/A12/31/20166-11N/A-10N/A9/30/20164-9N/A-8N/A6/30/20164-7N/A-6N/A3/31/20164-9N/A-8N/A12/31/20154-11N/A-10N/A9/30/20154-12N/A-10N/A6/30/20153-13N/A-10N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 0DOLの予測収益成長が 貯蓄率 ( 3.4% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 0DOLの収益がUK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 0DOLの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 0DOLの収益がUK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 0DOLの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 0DOLの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 17:56終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Biofrontera AG 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Raymond MyersBenchmark CompanyTsvetan KintisheffFirst Berlin Equity Research GmbHThomas FlatenLake Street Capital Markets, LLC3 その他のアナリストを表示
お知らせ • May 02Biofrontera AG, Annual General Meeting, Jun 10, 2026Biofrontera AG, Annual General Meeting, Jun 10, 2026, at 10:00 W. Europe Standard Time.
Reported Earnings • Apr 24Full year 2025 earnings released: €1.12 loss per share (vs €0.70 loss in FY 2024)Full year 2025 results: €1.12 loss per share (further deteriorated from €0.70 loss in FY 2024). Revenue: €13.2m (up 8.3% from FY 2024). Net loss: €6.81m (loss widened 61% from FY 2024). Over the last 3 years on average, earnings per share has increased by 117% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.
お知らせ • Oct 24Biofrontera Inc. (NasdaqCM:BFRI) completed the acquisition of US Assets related to Ameluz and RhodoLED of Biofrontera AG.Biofrontera Inc. (NasdaqCM:BFRI) signed an agreement to acquire US Assets related to Ameluz and RhodoLED of Biofrontera AG on June 30, 2025. The transaction coupled with an $11 million financing led by existing investors, Rosalind Advisors and AIGH Capital Management LLC, funded the acquisition and transfer costs. Upon completion, Biofrontera Inc. will pay a monthly Ameluz® royalty of 12% in years where Ameluz® revenue in the US is less than $65 million, and 15% in years when revenue exceeds that threshold. The new royalty replaces the former transfer pricing model which required payment of 25% to 35% of the net sales price per tube depending on timing and indication. As part of the agreement, Biofrontera AG will receive a 10% post-money equity stake in Biofrontera Inc., aligning long-term interests between the entities. Biofrontera Inc. (NasdaqCM:BFRI) completed the acquisition of US Assets related to Ameluz and RhodoLED of Biofrontera AG on October 23, 2025. On completion, Biofrontera Inc. now assumes full responsibility for manufacturing, regulatory, quality management, pharmacovigilance, and commercialization of Ameluz ® and the RhodoLED ® portfolio in the U.S. The Company expects the full transfer of assets and personnel to be completed by late Q4 2025 or early Q1 2026.
お知らせ • Apr 18Biofrontera AG, Annual General Meeting, May 28, 2025Biofrontera AG, Annual General Meeting, May 28, 2025, at 10:00 W. Europe Standard Time.
お知らせ • Dec 16+ 3 more updatesBiofrontera AG to Report Fiscal Year 2024 Results on Apr 30, 2025Biofrontera AG announced that they will report fiscal year 2024 results at 12:00 PM, Central European Standard Time on Apr 30, 2025
お知らせ • Nov 24Biofrontera AG announced that it has received $4.2 million in fundingBiofrontera Inc. announced a private placement to issue senior secured convertible note for the gross proceeds of $4,200,000 on November 22, 2024. The transaction included participation from two majority shareholders. The Note matures on November 22, 2027, bears a paid in kind interest of 10% per annum and is secured by the Company’s assets. The principal amount of the Note in whole or in part is convertible into common shares at the holder’s discretion at a fixed conversion price of $0.78. Alternatively, the entire amount of the note will be automatically converted to common shares if the 10-day volume weighted average price (VWAP) of Company shares on Nasdaq is greater than $2.50, and certain other conditions are met. The Notes contain customary restrictive covenants that, among other things, generally limit the ability of the Company to (i) create liens, (ii) pay dividends or acquire shares of capital stock, (iii) incur indebtedness, or (iv) enter into transactions with affiliates. The foregoing restrictive covenants are subject to a number of important exceptions and qualifications, as set forth in the Notes.
お知らせ • Sep 26Biofrontera AG to Report First Half, 2024 Results on Sep 30, 2024Biofrontera AG announced that they will report first half, 2024 results on Sep 30, 2024
お知らせ • Jul 23Biofrontera AG, Annual General Meeting, Aug 28, 2024Biofrontera AG, Annual General Meeting, Aug 28, 2024, at 10:00 W. Europe Standard Time.
お知らせ • May 16Biofrontera AG to Report Q1, 2024 Results on May 31, 2024Biofrontera AG announced that they will report Q1, 2024 results on May 31, 2024
お知らせ • Apr 24Biofrontera AG to Report Fiscal Year 2023 Results on Apr 30, 2024Biofrontera AG announced that they will report fiscal year 2023 results at 12:00 PM, Central European Standard Time on Apr 30, 2024
お知らせ • Nov 07Biofrontera AG to Report Q3, 2023 Results on Nov 28, 2023Biofrontera AG announced that they will report Q3, 2023 results on Nov 28, 2023
お知らせ • Jul 14Biofrontera AG to Report First Half, 2023 Results on Aug 31, 2023Biofrontera AG announced that they will report first half, 2023 results on Aug 31, 2023
お知らせ • Jul 06Biofrontera Launches Novel Belixos Active CareBiofrontera announced that the active cosmetic series belixos has been extended by the care foam belixos ACTIVE CARE. belixos ACTIVE CARE is a skin-so clothing care foam for irritated and itchy skin that can be used as basic care for atopic dermatitis and psoriasis, as well as for soothing intensive care for everyday skin problems. With its innovative formulation as a foam, it provides a pleasant feeling on the skin without a greasy film and enables particularly gentle application of the high-quality ingredients as a result of the reduced foam formulation. Due to it's innovative nature, Biofrontera was able to register the underlying innovative foam formulation as a patent. As previously in the belixos cosmetics series, the focus is on the traditional medicinal plant Mahonia as an active component. The medicinal plant, which is still quite unknown in European country but has been used for centuries in the medicine of the indigenous people of North America, is known to have anti-inflammatory, antipruritic and antiseptic properties. With the help of Biofrontera's proprietary biocolloid technology, the plant-based active ingredients penetrate very quickly into the epidermis and distribute there in order to unfold their soothing and regenerating effect in this very sensitive layer of skin that is particularly accessible to external influences.
お知らせ • May 30Biofrontera AG to Report Q1, 2023 Results on May 31, 2023Biofrontera AG announced that they will report Q1, 2023 results on May 31, 2023
お知らせ • May 18Biofrontera AG Completes Patient Recruitment of Ameluz Phase I TrialBiofrontera AG announced the successful completion of the Phase I study evaluating the safety and tolerability of Ameluz-PDT for the treatment of actinic keratosis (AK) with 3 tubes of Ameluz. This trial was conducted to expand the approval of Ameluz in the United States so that larger areas of AK-affected skin can be treated in one therapy session. The study involved 100 patients with mild to severe actinic keratosis, each of them receiving the contents of 3 tubes of Ameluz for a field-directed treatment of AK. Illumination was provided by Biofrontera's novel, larger RhodoLED XL lamp. The first results of the study are expected in the fourth quarter of 2023.
お知らせ • May 13Biofrontera AG, Annual General Meeting, Jun 20, 2023Biofrontera AG, Annual General Meeting, Jun 20, 2023, at 11:30 Central European Standard Time. Location: Forum Leverkusen, Agam-Saal, Am Büchelter Hof 9, Leverkusen Germany
Reported Earnings • Apr 30Full year 2022 earnings released: €0.77 loss per share (vs €0.69 profit in FY 2021)Full year 2022 results: €0.77 loss per share (down from €0.69 profit in FY 2021). Revenue: €25.7m (down 11% from FY 2021). Net loss: €44.2m (down 215% from profit in FY 2021). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.